Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

NICE technology appraisals [TA218] Published date:

NICE recommends azacitidine as a possible treatment for some adults with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia.

Who can have azacitidine?

People who cannot have a stem cell transplant may be able to have azacitidine. Azacitidine is 'licensed' (approved as being safe by the European regulatory agency) for adults with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia, but only in specific circumstances, for example, depending on the characteristics of the person's blood and bone marrow.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE recommended azacitidine because the cost is justified by the benefits it provides when the special considerations are applied.

Get involved